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ABSTRACT 
Background: Matrix metalloproteinases are enzymes involved in cardiovascular (CV) 
remodeling and hypertension-mediated target organ damage (TOD). Genetic 
polymorphisms in matrix metalloproteinase 2 (MMP-2) gene [-1575G/A (rs243866); -
1306C/T (rs243865); and -735C/T (rs2285053)] are associated with several CV 
conditions, however the relationship between MMP-2 polymorphisms and resistant 
hypertension (RH) is unknown. We evaluated whether these genetic single nucleotide 
polymorphisms (SNPs) in MMP-2 gene are associated with 1) MMP-2 and TIMP-2 
levels in RH and mild to moderate hypertensive (HT) subjects, 2) left ventricular 
hypertrophy (LVH) and arterial stiffness and 3) the presence of RH. Methods: One 
hundred and nineteen RH and 136 HT subjects were included in this cross-sectional 
study. Genotypes were determined by real-time PCR using TaqMan probes. Haplotypes 
were estimated using Bayesian method. Results: The levels of MMP-2 and TIMP-2 
were similar among genotypes and haplotypes for the three studied polymorphisms in 
HT and RH groups. RH showed higher frequency for GCC haplotype (-1575G/A, -
1306C/T and -735C/T, respectively) compared to HT (0.77 vs. 0.64, respectively), while 
HT had a higher frequency of GCT (0.17 vs. 0.09; p=0.003) and ATC (0.19 vs. 0.13; 
p=0.003, respectively) compared to RH. GCC haplotype was associated to RH apart 
from potential confounders (odds ratio (OR) =2.09; 95% confidence interval (CI)=1.20-
3.64; p=0.01). In addition, CC genotype (OR=2.93; 95% CI= 1.22–7.01; p=0.02) or C 
allele (OR=2.81; 95% CI=1.26–6.31; p=0.01) for -735C/T polymorphism were 
independently associated with RH. GCT haplotype was associated with reduced 
probability of having RH (OR=0.35; 95% CI=0.16–0.79; p=0.01). Finally, no 
relationship was found between studied MMP-2 SNPs and left ventricular hypertrophy 
and arterial stiffness in both groups. Conclusion: C allele, CC genotype and GCC 
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haplotype for -735C/T polymorphism in MMP-2 gene were associated with high 
probability of having RH, while GCT haplotype showed reduced probability of RH.  
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polymorphism, target organ damage. 
 
 Highlights: 
 MMP-2 polymorphisms [-1575G/A (rs243866); -1306C/T (rs243865); and -
735C/T (rs2285053)] were studied to analyze its association with resistant 
hypertension and target organ damage. 
 In -735C/T MMP-2 polymorphism, the C allele and CC genotype were 
associated with the presence of resistant hypertension. 
 Resistant hypertensive group had higher frequency of GCC haplotype, while 
mild to moderate hypertensive group had higher frequency of GCT and ATC 
haplotypes.  
 GCC haplotype was associated with resistant hypertension, while GCT 
haplotype was associated with lower probability of having resistant 
hypertension. 
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1. INTRODUCTION 
 Resistant hypertension (RH) has been associated with higher cardiovascular 
(CV) risk [1] and increased prevalence of target organ damage (TOD) compared to 
controlled hypertension [2, 3].  Several studies have suggested the involvement of 
metalloproteinases in CV remodeling contributing to TOD development [4, 5].  
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases 
associated to extracellular matrix (ECM) reorganization. One of the most studied 
MMPs, the matrix metalloproteinase 2 (MMP-2) is associated with degradation of  
several vascular and cardiac proteins including type IV collagen, interstitial collagen 
types I, II and III, troponin I, and myosin light chain and poly(ADP-ribose) polymerase 
contributing to cardiac dysfunction [6]. In addition, MMP-2 has been associated with 
hypertension and vascular injury [4, 5]. MMP-2 is regulated at the transcriptional and 
posttranslational levels. It is activated by cleavage of zymogens and by interaction with 
endogenous inhibitor, known as tissue inhibitor of metalloproteinases 2 (TIMP-2) [6]. 
Genetic polymorphisms in the MMP-2 gene [-1575G/A (rs243866); -1306C/T 
(rs243865); and -735C/T (rs2285053)] have been implicated in the pathogenesis of 
several CV conditions, such as myocardial infarction [7], stroke [8], left ventricular 
remodeling in hypertension [9] and coronary disease [10]. However, the relationship 
between polymorphisms in MMP-2 gene and resistant hypertension and TOD in this 
population remains unexplored. The aims of this study were to evaluate the association 
of MMP-2 single nucleotide polymorphisms (SNPs) (-1575G/A, rs243866; -1306C/T, 
rs243865; and -735C/T, rs2285053) with 1) MMP-2 and TIMP-2 levels; 2) left 
ventricular hypertrophy (LVH) and arterial stiffness in all hypertensive subjects, and 3) 
the presence of RH.  
2. METHODS 
2.1. Study Population 
One hundred and nineteen RH patients and 136 mild to moderate hypertensive 
(HT) patients were included in this cross-sectional study. RH patients were regularly 
followed at the Outpatient Resistant Hypertension Clinic of the University of Campinas 
(Campinas, Brazil) and at the Hypertension Clinic of Valinhos (Brazil). The diagnostic 
of RH was performed according to American Heart Association criteria after 6-months 
of follow-up. RH was defined as blood pressure (BP) that remains above the BP goal 
(≥140/90 mmHg) despite the use of 3 or more different classes of antihypertensive 
drugs at optimal doses, or use of 4 or more antihypertensive drugs with controlled BP 
[11]. In this period we assessed office BP, ambulatory BP monitoring (ABPM) 
measurements and biochemical exams in all patients. We excluded secondary 
hypertension (primary hyperaldosteronism, renal artery stenosis and 
pheochromocytoma), pseudoresistance (white-coat hypertension) and lack of treatment 
adherence (determined by Morisky questionnaire and pill counts) to identify true 
resistance to the treatment [11]. Patients with controlled BP taking at least 3 
antihypertensive drugs were considered HT. This study was approved by the Research 
Ethics Committee at the Faculty of Medical Sciences of University of Campinas 
(Campinas, Brazil) (approval no 188.161/2013) and conducted in compliance with the 
guidelines of the Declaration of Helsinki. All participants signed an informed written 
consent form.  
2.2. Inclusion and Exclusion Criteria 
The inclusion criteria comprise the diagnosis of non-resistant or resistant 
hypertension; regular follow-up for at least six months; adherence assessment using 
questionnaires; volunteer participation and informed consent signature. 
Patients with medical history or clinical symptoms of heart failure (ejection 
fraction < 50%); valvular or pericardial heart diseases; presence of cardiomyopathy; 
diagnosis of coronary and peripheral vascular disease; autoimmune diseases; 
nephropathy; liver dysfunction; and pregnancy or declared intention to become pregnant 
were excluded. 
2.3. Blood pressure measurements 
Office systolic BP (SBP) and diastolic BP (DBP) were evaluated at least three 
times using a digital BP monitor (OMRON Healthcare Inc., Bannockburn, IL, USA) 
with a 3-minute interval between the measurements. Patients were monitored 
approximately at 8:00 am, in a seated position after a 10-minute rest.  
ABPM was performed through twenty-four hour BP monitoring by an automatic 
oscillometric device (Spacelabs 90207, Spacelabs Inc, Redmon, WA, USA). Patients 
were instructed to keep their normal daily activities and the BP was measured 
automatically at a 20-min interval during 24-h period. 
2.4. Echocardiography  
  Left ventricular (LV) dimensions were measured using M-mode 
echocardiography by a cardiovascular ultrasound machine (Siemens Acuson CV70; 
Munich, Bavaria, Germany), according to the American Society of Echocardiography 
(ASE) recommendations [12]. Diastolic and systolic left ventricle diameters, 
interventricular septal and posterior wall thicknesses were measured according to the 
QRS wave of electrocardiography at the end of diastole. LV mass index (LVMI) was 
calculated according to the ASE recommendations, dividing LV mass by the body 
surface. Left ventricular hypertrophy (LVH) was determined by LVMI ≥115 g/m2 for 
men and ≥95 g/m2 for women. 
 
2.5. Aortic PWV measurement 
Pulse wave velocity (PWV) measurements were obtained using Sphygmocor 
system (Artcor, Sidney, Australia) to estimate arterial stiffness. Pulse waves were 
obtained transcutaneously using a tonometer at the right common carotid and femoral 
arteries. The distance covered by the waves was measured directly between the femoral 
recording site and the supra sternal notch minus the distance from the supra sternal 
notch to the carotid recording site. PWV was calculated as distance (meters)/Δt 
(seconds) [13]. Three consecutive readings were collected to determine the PWV 
average value that was used in analyses. Arterial stiffness was defined as PWV higher 
than 10 m/s. 
2.6. Biochemical measurements  
Blood samples were obtained after overnight fasting period by venipuncture. 
Heparin-anticoagulated blood samples were centrifuged at 5,300 rpm for 10 minutes to 
obtain plasma samples. EDTA-anticoagulated total blood samples were collected for 
DNA extraction. The samples were immediately stored at -80ºC until the measurements. 
MMP-2 and TIMP-2 were measured by enzyme-linked immunosorbent assay (ELISA) 
(R&D Systems, Inc., Minneapolis, USA) and plasma aldosterone concentration was 
measured by radioimmunoassay (Immunotech SAS, Marseille, France) according to the 
manufacturer’s instructions. Creatinine clearance (ml/min/1.73 m2) and urine albumin-
to-creatinine ratio (mg/g) were measured in urine sample collected during consecutive 
24 hours. Urine albumin-to-creatinine ratio (mg/g) was used to evaluate 
microalbuminuria (values < 30mg/g were classified as normal and values between 30 
and 300mg/g as microalbuminuria).  
 
 
2.7. Determination of genotypes  
Genomic DNA was extracted using the Illustra blood genomic Prep Mini Spin 
Kit (GE Healthcare, Buckinghamshire, UK) from total blood according to the 
manufacturer’s instructions. MMP-2 genotypes of the SNPs -1575 G/A (rs243866), -
1306 C/T (rs243865), and -735 C/T (rs2285053) were determined using the TaqMan 
allelic discrimination assay (assays ID C_3225942_10, C_3225943_10 and 
C_26734093_20, respectively; Applied Biosystems, Foster City, CA, USA). DNA 
quality and quantity was checked by NanoDrop spectrophotometer (ThermoScientific, 
Wilmington, USA). Polymerase chain reaction (PCR) was conducted with 5 ng of DNA 
following the steps: (i) 10 minutes at 95°C; (ii) 40 cycles of DNA denaturation at 90°C 
for 15 seconds; and (iii) annealing/extension at 60°C for 1 minute. Fluorescence signals 
were detected using StepOnePlus Real Time PCR System (Applied Biosystems, Foster 
City, CA, USA) and analyzed using the StepOne
TM
 software version 2.1. 
2.8. Haplotype inference 
Haplotypes combinations for the 3 MMP-2 polymorphisms ordered according to 
their location in the chromosome (-1575G/A (rs243866); -1306C/T (rs243865); and -
735C/T (2258053), respectively) were inferred using the Bayesian statistical-based 
program PHASE (version 2.1; http://www.stat.washington.edu/stephens/software.html) 
[14]. Three haplotype combinations were found in these populations including the 3 
MMP-2 polymorphisms ordered according to their location in the chromosome (-
1575G/A (rs243866); -1306C/T (rs243865); and -735C/T (2258053), respectively. The 
estimated haplotypes were GCC, GCT and ATC. The haplotypes with observed 
frequencies <1 % in all groups were excluded from subsequent analyses.  
 
 
2.9. Statistical analysis 
Continuous variables were expressed as mean and standard deviation or median 
and 1
st
 and 3
rd
 quartiles, according to data distribution. Data distribution was assessed 
by Shapiro–Wilk test. We performed Student’s t-test or Mann–Whitney test to compare 
two groups, while Kruskal–Wallis or analysis of variance (ANOVA) test were 
performed to compare three groups, followed by Dunns or Bonferroni multiple 
comparison test. Categorical variables were presented in frequencies and/or percentages 
and compared by chi-square or Fisher’s test. Hardy–Weinberg equilibrium was 
evaluated by chi-square test. We used the dominant genetic model to test the association 
of these polymorphisms with MMP-2 levels and clinical features for all three 
polymorphisms. AA and AG genotypes of the rs243866 (-1575G/A) polymorphism 
were gathering as one group, denoted by “A carriers” due to the low frequency of the 
minor allele. We used the same approach with TT genotype in the rs243865 (-1306C/T) 
polymorphism and for TT genotype in rs2285053 (-735C/T) polymorphisms. Thus, we 
analyze the TT and CT as one group - T carriers). Multiple logistic regression analyses 
were performed by SigmaPlot program version 12.5 (Systat Software, Inc., USA) to 
evaluate individually the effect of haplotype, genotype and allele on RH presence 
(adjusted for age, gender, self-declared race, body mass index (BMI) and glycated 
hemoglobin). The level of statistical significance accepted was 0.05. We considered the 
alpha error of 0.017 (0.05/3 polymorphisms) as statistically significant for genotype and 
haplotype analyses.  
2.10. Results 
General characteristics of HT and RH groups are shown in Table 1. Subjects 
differ in age, race, diabetes, BMI, waist circumference, fat mass, office SBP, LVMI and 
PWV. In addition, RH subjects presented higher cholesterol and LDL levels, HbA1c, 
glucose, microalbuminuria, aldosterone levels and TIMP-2 levels compared to HT 
group. Decreased MMP-2/TIMP-2 ratio was found in RH group. Drug distribution is 
show in table 1. For most of the medications, RH is taking a higher proportion of 
medications compared to HT, except for angiotensin receptor blocker and statins, which 
were higher in HT group.  
Allele, genotype and haplotype frequencies are shown in Table 2. No deviation 
from Hardy–Weinberg equilibrium (p>0.05) in the studied polymorphisms was found. 
Allele and genotype frequencies between RH and HT groups were similar for all studied 
MMP-2 polymorphisms (p<0.017). On the other hand, RH had higher frequency for 
GCC haplotype compared to HT and HT had a higher frequency of GCT and ATC 
(p=0.003) (table 2).  
No difference was found between the MMP-2 and TIMP-2 levels according to 
genotype in each polymorphism for both RH and HT groups (figure 1). Also, we did not 
find difference in the MMP-2 and TIMP-2 levels comparing haplotypes GCC, GCT and 
ATC in RH (MMP-2 levels p=0.64; TIMP-2 levels p=0.97) and HT (MMP-2 levels 
p=0.64; TIMP-2 levels p=0.32) groups. Furthermore, no association was found among 
the studied SNPs (alleles, genotypes and haplotypes) with LVH, arterial stiffness and 
microalbuminuria in both groups (table 3).  
Finally, GCC haplotype was independently associated with RH apart from 
potential confounders. In addition, CC genotype and C allele of -735C/T polymorphism 
were associated with the presence of RH. On the other hand, GCT haplotype was 
associated with lower probability of having RH (table 4). 
2.11. Discussion 
We found different haplotype frequencies between HT and RH groups (GCC, 
GCT and ATC, for -1575G/A; -1306C/T; -735C/T). GCC haplotype was associated to 
RH phenotype, while GCT haplotype was associated to lower probability of having RH. 
The CC genotype and the C allele of -735C/T (rs2285053) polymorphism in MMP-2 
gene were also associated to RH.  
Previous studies have showed the importance of MMP-2 in CV remodeling [15],  
in hypertension [16]  and in TOD development [15]. In addition, patients with increased 
MMP-2 levels associated with particular genotypes or haplotypes may be exposed at 
increased risk of CV complications [17]. MMP-2 plays a central role in the degradation 
of ECM components, both in physiological and in pathophysiological conditions [18, 
19], thus there is growing interest to know whether polymorphisms in the MMP-2 gene 
are associated to altered MMP-2 levels and development of hypertension and TOD. 
MMP-2 gene is located on chromosome 16 and variations in the DNA sequence 
in promoter region might affect transcriptional activity of the adjacent gene [20, 21]. 
We studied 3 SNPs located in the promoter region of MMP-2 [-1306C/T (rs243865), -
1575G/A (rs243866) and -735C/T SNP (rs2258053)], that have been associated to 
altered MMP-2 expression in CV diseases [7, 9, 22]. The MMP-2 polymorphisms -
1306C/T and -735C/T SNPs disrupts a Sp1 promoter site decreasing the promoter 
activity in the presence of the T allele [20, 21] . In addition,  evidences suggest that the 
G/A transition in the –1575G/A polymorphism located in promoter region, also reduces 
MMP-2 transactivation activity [23]. Although these studies showed the influence of 
MMP-2 polymorphisms in MMP-2 levels, we did not find difference in MMP-2 levels 
and TIMP-2 levels according to genotypes and haplotypes for each polymorphism (-
1306C/T, -1575G/A and -735C/T) in both hypertensive groups. In fact, hypertension is 
a multifactorial and complex pathogenesis and the high number of different medications 
may influence the levels of MMP-2 [24-26]. In addition, it is likely that these results 
arise from either interactions of the SNPs with environmental factors or other 
polymorphisms in MMP-2 gene, from the studied population, or from the model used in 
statistical analysis.  
The genetic association studies with MMP-2 polymorphisms and hypertension 
are scarce and still controversial. Some studies have shown that -1306C/T, -735C/T and 
-1575G/A polymorphisms are not related to hypertension [9, 22, 27-29]. Researchers 
have also been exploring the association of these polymorphisms with cardiovascular 
diseases (CVD) and with hypertension-related TOD. The majority of the studies have 
shown that neither the -1575 polymorphism [30-33] nor the -1306C/T polymorphism 
are associated with increased risk to develop CVD and TOD [10, 30, 34-37]. Similarly, 
our results showed no association between these polymorphisms and TOD in resistant 
hypertension.   
Finally, previous studies have showed that the -735TT genotype was associated 
with increased risk of myocardial infarction [30], while another study suggested TT 
genotype and T allele as protective factors in subjects with vulnerable plaques [38].  
Also, the C allele was associated to chronic heart failure [31] and with ischemic stroke 
[36]. Conversely, other studies have shown no relationship between the -735C/T 
polymorphism and other comorbidities including atrial fibrillation [34] and LVMI [9] in 
hypertensive patients, left ventricular dysfunction in coronary artery disease patients 
[39] and risk of developing coronary artery disease [37]. Importantly, we found that C 
allele and CC genotype for -735 polymorphism are both independently associated with 
resistant hypertension, although this SNP does not modulate MMP-2 levels. In 
agreement with this, C carriers presented higher probability to have chronic heart failure 
[31] and ischemic stroke [36], suggesting that C allele is related to similar CV 
alterations involved in the pathogenesis of RH, apart from its modulatory effects on 
MMP-2 levels. This polymorphism may also be in linkage disequilibrium with 
regulatory sequences modulating transcription of MMP-2 gene, potentially explaining 
the lack of alteration in MMP-2 levels.  
The main limitations of this work includes: i) The small number of patients 
included; ii) Patients were under pharmacological treatment, which may be a possible 
confounder for MMP-2 levels; iii) Study power: the lack of association in MMP-2 or 
TIMP-2 levels may be attributed to low power to detect any difference between 
genotypes/haplotypes groups. Thus, these findings need to be replicated in independent 
and larger studies to confirm our findings.   
2.11.1 Conclusion 
The GCC haplotype was associated to the presence of RH, while the GCT 
haplotype may act as a protective factor due to its association with lower probability of 
having RH. Moreover, the association among the former mentioned haplotypes and RH 
seems to be independent of MMP-2 levels, supporting our hypothesis that this MMP-2 
SNP may affect the susceptibility for RH as a MMP-2 levels-independent mechanism. 
However, we cannot rule out that MMP-2 levels were affected by several 
antihypertensive drugs taking in RH, which could explain our negative findings. Those 
haplotype associations with RH may be driven by -735C/T polymorphism or other 
SNPs in linkage disequilibrium in MMP-2 gene region.   
In the present study, we demonstrated for the first time that the GCC and GCT 
haplotypes, and the C allele and CC genotype of the -735C/T MMP-2 gene 
polymorphism are associated with the presence of RH. 
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Abbreviation List 
 
Resistant hypertension (RH)  
Cardiovascular (CV) 
Target organ damage (TOD) 
Matrix metalloproteinases (MMPs)  
Extracellular matrix (ECM) reorganization  
Matrix metalloproteinase 2 (MMP-2) 
Tissue inhibitor of metalloproteinases 2 (TIMP-2) 
Single nucleotide polymorphisms (SNPs) 
Left ventricular hypertrophy (LVH) 
Mild to moderate hypertensive (HT) 
Blood pressure (BP) 
Ambulatory blood pressure monitoring (ABPM) 
Systolic blood pressure (SBP)  
Diastolic blood pressure (DBP) 
Left ventricular (LV) 
American Society of Echocardiography (ASE) 
Left ventricular mass index (LVMI) 
Left ventricular hypertrophy (LVH) 
Pulse wave velocity (PWV) 
Enzyme-linked immunosorbent assay (ELISA) 
Analysis of variance (ANOVA) 
Body mass index (BMI) 
Low-density lipoprotein (LDL)  
Glycated hemoglobin (HbA1c) 
Cardiovascular diseases (CVD) 
*Abbreviations list
Table 1 – General characteristics of mild-moderate hypertensive (HT) and resistant 
hypertensive patients (RH) 
 
 HT RH P-value 
N 136 119 - 
Clinical Parameters    
Age (years) 65 ± 10 60 ± 11 < 0.01 
Gender (F %) 62 66 0.51 
Race non-W (%) 13 44 <0.01 
Diabetes (%) 37 50 0.04 
BMI (Kg/m
2
) 27.6 (24.6-31.8) 30.8 (26.9-34.9) < 0.01 
Waist circumference (cm) 93.8 (12.8-1.2) 101.1 (14.4-1.6) <0.01 
Fat Mass (Kg) 19.9 (14.6-27.0) 25.9 (19.1-35.1) <0.01 
Office SBP (mmHg) 139 (131-148) 147 (134-159) < 0.01 
Office DBP (mmHg) 81(76-86) 82 (77-91) 0.11 
ABPM SBP (mmHg)  126 (118-135) 129 (116-142) 0.22 
ABPM DBP (mmHg)  76 (70-81) 76 (70-85) 0.40 
LVMI (g/m
2
) 100.0 (86.5-119.0) 116.6 (94.7-142.1) < 0.01 
PWV (m/s) 9.8 (8.6-11.6) 9.2 (7.6-11.1) 0.03 
Biochemical Parameters    
Total Cholesterol (mg/dL) 165 (140-185) 181 (150-207) < 0.01 
LDL (mg/dL) 86 (67-107) 97 (79-127) < 0.01 
Hb A1c (%) 6.0 (5.8-6.4) 6.3 (5.9-7.8) < 0.01 
Glucose (mg/dL) 97(90-107) 101 (89-132) 0.11 
Creatinine (mg/dL) 0.9 (0.8-1.1) 1.0 (0.8-1.2) 0.18 
Creatinine Clearance (mL/min/1.73m
2
) 65(28-93) 81 (61-98) 0.05 
Albumin/Creatinine (mg/g) (n=39) 6.1 (4.3-13.2) (n=83) 14 (7.7-80.7) < 0.01 
C-reactive protein (mg/dL) 0.3(0.1-0.6) 0.3 (0.1-0.6) 0.44 
Aldosterone (pg/mL) 67.5 (42.5-114.5) 97.9 (60.7-176.9) < 0.01 
MMP-2 (ng/mL) 240.1 (200.6-285.1) 239.1(187.4-308.9) 0.91 
TIMP-2 (ng/mL) 70.9 (57.0-89.5) 89.1 (75.3-106.5) <0.01 
MMP-2 / TIMP-2 3.4 (2.6-4.4) 2.6 (2.0-3.5) <0.01 
Medications    
Diuretics 90 (67) 108 (94) <0.01 
Calcium channel blockers 59 (44) 102 (89) <0.01 
β-blockers                                                      19 (14) 83 (72) <0.01 
Angiotensin receptor blockers 101 (75) 67 (58) <0.01 
Spironolactone 2 (1) 46 (40) <0.01 
Angiotensin-converting enzyme inhibitors 22 (16) 44 (38) <0.01 
Sympatholytic drugs 1 (1) 34 (29) <0.01 
Table(s)
Statins 102 (75) 69 (60) <0.01 
Data expressed as mean ± SD or median (1
st
, 3
rd
 quartiles). HT = mild-moderate hypertensive; RH = resistant 
hypertensive; N = sample size; F = female; non-W = nonwhite; BMI = body mass index; SBP = systolic blood 
pressure; DBP = diastolic blood pressure; ABPM = ambulatory blood pressure monitoring; LVMI = left 
ventricular mass index; PWV = Pulse wave velocity; LDL = low-density lipoprotein; HbA1c = glycated 
hemoglobin; MMP-2 = matrix metalloproteinase-2; TIMP-2= tissue inhibitor of metalloproteinase 2. 
 
 
Table 2 – Allele, genotype and haplotype frequencies for MMP-2 polymorphisms in 
mild-moderate (HT) and resistant hypertensive (RH) subjects 
 HT (N=136) RH (N=119) P-value 
Allele    
-1575G/A (rs243866)     
G 0.81  0.87  0.09 
A 0.19  0.13   
-1306C/T (rs243865)    
C 0.81 0.87  0.12 
T 0.19  0.13   
-735C/T rs2285053    
C 0.83  0.90  0.02 
T 0.17  0.10  
Genotype    
-1575G/A (rs243866)    
GG 0.64  0.74   
AG 0.34  0.25  0.20 
AA 0.02  0.008   
-1306C/T (rs243865)    
CC 0.64  0.74   
CT 0.33  0.25  0.22 
TT 0.02  0.008   
-735C/T (rs2285053)    
CC 0.68  0.81   
CT 0.29  0.17  0.04 
TT 0.02  0.008  
Haplotype    
GCC 0.64  0.77   
GCT 0.17  0.09  0.003 
ATC 0.19  0.13   
HT= mild-moderate hypertensive; RH = resistant hypertensive. Data are expressed as relative frequency 
(%) and number (n). Chi-square test was used to compare genotype and haplotype distribution between 
groups and Fisher's test was used to compare allele frequencies between groups. The haplotypes correspond 
to -1575 G/A (rs243866) -1306 C/T (rs243865) and -735 C/T (rs2285053) polymorphisms, respectively. p< 
0.017.  
 Table 3 – Genotypes frequencies of MMP-2 polymorphisms according to the presence 
of left ventricular hypertrophy, arterial stiffness and renal dysfunction in RH and HT 
groups 
 
LVH= Left ventricular hypertrophy (≥115 g/m2 for men and ≥95 g/m2 for women); 
Microalb= microalbuminuria; PWV= pulse wave velocity. Fisher’s test was used to 
compare categorical variables between genotypes. * p<0.05 
 
Table 4 – Logistic Regression to explore the association of  C allele and CC genotype 
of -735 C/T polymorphism and haplotypes with the presence of resistant hypertension 
               OR (5%-95%CI) p-value 
Haplotype GCC 2.09 (1.20 - 3.64) 0.01 
Haplotype GCT 0.35 (0.16 – 0.79) 0.01 
Genotype CC -735C/T (rs2285053) 2.93 (1.22 – 7.01) 0.02 
Allele C -735C/T (rs2285053)         2.81 (1.26 – 6.31) 0.01 
Haplotypes correspond to -1575 G/A (rs243866), -1306 C/T (rs243865) and -735 
C/T (rs2285053) polymorphisms. The analyses were individually evaluated for each 
haplotype, genotype and allele. Adjusted by age, gender, race, BMI and glycated 
hemoglobin. 
 Left ventricular 
hypertrophy 
Renal dysfunction            
(Microalb> 30mg/g) 
Arterial stiffness 
(PWV>10m/s) 
RH    
-1575G/A (rs243866)    
GG 63 % 33% 36 % 
A carriers 71 % 50% 52 % 
-1306C/T (rs243865)    
CC  63 % 33% 36 % 
T carriers 72 % 50% 50 % 
-735C/T (rs2285053)    
CC 66 % 41% 40 % 
T carriers 61 % 15% 39 % 
HT    
-1575G/A (rs243866)    
GG 50 % 11% 49 % 
A carriers 42 % 15% 47 % 
-1306C/T (rs243865)    
CC  50 % 11% 49 % 
T carriers 43 % 17% 48 % 
-735C/T (rs2285053)    
CC 45 % 9% 48 % 
T carriers 56 % 20% 52 % 
 Figure 1 – MMP-2 and TIMP-2 plasma levels according to genotype in each 
polymorphism in RH and HT group. 
a) 
 
b) 
 
Panel A shows MMP-2 levels and TIMP-2 in RH patients; Panel B shows MMP-2 
levels and TIMP-2 levels in HT patients. p< 0.05. 
 
Figure(s)
